KOREA WHO
-
-
-
CEO of ToolGen
Ryu Jong-sang
Samsung, Daewoong Veteran Bets on CRISPR Patent Victory
-
Last Updated on Sep 9, 2025
-
CEO of ToolGen
Life Summary
Ryu Jong-sang is the CEO of ToolGen.
He faces the task of establishing a sustainable revenue base after winning a patent dispute over gene-editing technology.
He was born on May 4, 1971.
He received his Ph.D. in Molecular Biology and Molecular Genetics from Pohang University of Science and Technology (POSTECH).
In 2005, he began his professional career as a researcher at the National Core Research Center for Systems Bio-Dynamics.
He worked as a senior research scientist at Samsung Advanced Institute of Technology (SAIT) Biohealth Lab and Samsung Bioepis.
He then served as Head of Strategic Planning at Theragen Etex Bio Research Institute, Head of Development at Daewoong Bio, and Head of the Cell Therapy Center at Daewoong Pharmaceutical, before being appointed CEO (CSO) of Apicell Therapeutics in 2021.
In March 2025, he was recruited as CEO of ToolGen.
He has also worked as a research fellow at the government’s Institute for Basic Science (IBS), conducting advanced basic science research.
He brings both research expertise in the field of cell and gene therapies and management experience in the biopharmaceutical industry.
#ToolGen #RyuJongsang #genetherapy #celltherapy #biopharma #genomeediting #patentdispute #POSTECH #SamsungBioepis #DaewoongPharma
He faces the task of establishing a sustainable revenue base after winning a patent dispute over gene-editing technology.
He was born on May 4, 1971.
He received his Ph.D. in Molecular Biology and Molecular Genetics from Pohang University of Science and Technology (POSTECH).
In 2005, he began his professional career as a researcher at the National Core Research Center for Systems Bio-Dynamics.
He worked as a senior research scientist at Samsung Advanced Institute of Technology (SAIT) Biohealth Lab and Samsung Bioepis.
He then served as Head of Strategic Planning at Theragen Etex Bio Research Institute, Head of Development at Daewoong Bio, and Head of the Cell Therapy Center at Daewoong Pharmaceutical, before being appointed CEO (CSO) of Apicell Therapeutics in 2021.
In March 2025, he was recruited as CEO of ToolGen.
He has also worked as a research fellow at the government’s Institute for Basic Science (IBS), conducting advanced basic science research.
He brings both research expertise in the field of cell and gene therapies and management experience in the biopharmaceutical industry.
#ToolGen #RyuJongsang #genetherapy #celltherapy #biopharma #genomeediting #patentdispute #POSTECH #SamsungBioepis #DaewoongPharma